Clients turn to Bill for his sharp judgment and clarity when navigating complex patent portfolio management, life-cycle planning, and Hatch-Waxman litigation strategy. He is particularly adept at guiding companies through freedom-to-operate and validity analyses, IP due diligence, and global patent portfolio development. His approach reflects both legal precision and commercial awareness — qualities that consistently earn the trust of both legal departments and executive leadership.

Bill has been consistently recognized for his excellence in patent law and client service across numerous prestigious industry rankings. He has been honored by LMG Life Sciences as Patent Strategy Attorney of the Year – Midwest in 2021 and was named a Life Sciences Star from 2012 to 2019 and again from 2022 to 2024. In 2025, he was shortlisted for Practitioner of the Year – Patent Prosecution USA by Managing IP, further underscoring his prominence in the field. Bill is listed in Intellectual Asset Management’s IAM Patent 1000 from 2022 to 2025 as one of the world’s leading patent practitioners and has been recognized by The Best Lawyers in America for both 2024 and 2025. He received the firm’s Client Service Award in 2023, reflecting his dedication to client-focused counsel.

Over the course of his career, Bill has led biotechnology and patent prosecution practice groups and continues to be a trusted strategic advisor to companies at the forefront of innovation. His ability to synthesize technical detail, business objectives, and legal risk makes him a go-to resource in the life sciences sector.

Bill is not admitted to practice law in the Commonwealth of Massachusetts. His practice exclusively involves matters of federal law in federal courts or before federal agencies, including the United States Patent and Trademark Office.